Vancouver, British Columbia--(Newsfile Corp. - May 4, 2015) - THC BioMed Intl Ltd. (CSE: THC) ("THC") is pleased to provide a shareholder update on its newly acquired wholly owned subsidiaries and listing on the Canadian Stock Exchange ("CSE").
On April 29, 2015, THC was listed and began trading on the CSE. THC offers consulting services to MMPR license applicants and has two MMPR License applications currently being reviewed by Health Canada.
THC has two, 100%-owned subsidiaries, THC BioMed Ltd. And T.H.C Meds, both of which THC acquired in January 2015. THC BioMed was granted in August 2013 an Exemption 56 by The Office of Controlled Substances to conduct Scientific Research and Development with Medical Marihuana for a 1 year term, which expired in August 2014. This exemption permitted THC BioMed to cultivate, research, destroy and conduct in vitro testing at its in house state of the art laboratory.
THC BioMed's laboratory and research center in Kelowna, B.C. had a pre-licensing inspection conducted by Health Canada on 22 January 2015.
As our applications progress through the licensing process, we continue to advance our research into products and services as well as develop a standard of excellence in the research & Development of Medical Cannabis.
Having successfully navigated our way to stage 7 of Health Canada's 7 step MMPR License application process and having had our pre-licensing inspection completed has given us invaluable experience. It is our intention to generate immediate revenue by offering consulting services to aspiring licensed producers.
Our consulting services are available to all applicants at all stages of the application process with simulated inspections available for late stage applicants awaiting the pre-licensing inspection. We understand the difficulties faced by aspiring licensed producers and the lack of credible information available in the marketplace. We see a need for a legitimate consulting service provider for this sector.
Our vision is to be on the leading edge of the scientific research and development of products and services related to the Medical Cannabis industry while creating a standard of excellence. As the industry develops it will become more important to focus on scientific research and development of products and services related to Medical Cannabis. We are well positioned to be in the forefront of this rapidly growing industry.
Please visit our website for a more detailed description of our business and services available. www.thcbiomed.com
President and CEO:
John Miller
THC Biomed Intl Ltd.
T: 604 682-1643
E: info@thcbiomed.com
Forward-Looking Information:
This press release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. These statements are based on is based on expectations and assumptions made by the management of THC Biomed Intl Ltd. at the date the information is provided, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. For a description of the risks and uncertainties facing THC and its business and affairs, readers should refer to THC's Listing Statement and its Management's Discussion and Analysis on www.sedar.com.
copyright (c) newsfile corp. 2015. all rights reserved